Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections.

Tober-Lau, Pinkus; Gruell, Henning; Vanshylla, Kanika; Koch, Willi M; Hillus, David; Schommers, Philipp; Suárez, Isabelle; Suttorp, Norbert; Sander, Leif Erik; Klein, Florian; Kurth, Florian

Tober-Lau, Pinkus; Gruell, Henning; Vanshylla, Kanika; Koch, Willi M; Hillus, David; Schommers, Philipp; Suárez, Isabelle; Suttorp, Norbert; Sander, Leif Erik; Klein, Florian; Kurth, Florian.

Emerg Infect Dis ; 28(5): 1050-1052, 2022 05.

Article in English | MEDLINE | ID: covidwho-1731731

ABSTRACT

ABSTRACT

To determine neutralizing activity against the severe acute respiratory syndrome coronavirus 2 ancestral strain and 4 variants of concern, we tested serum from 30 persons with breakthrough infection after 2-dose vaccination. Cross-variant neutralizing activity was comparable to that after 3-dose vaccination. Shorter intervals between vaccination and breakthrough infection correlated with lower neutralizing titers.

Subject(s)

COVID-19; Antibodies, Neutralizing; Antibodies, Viral; Humans; SARS-CoV-2; Vaccination

Keywords

2019 novel coronavirus disease; B cell; COVID-19; SARS-CoV-2; coronavirus disease; immunity; mRNA; neutralizing antibody; respiratory infections; severe acute respiratory syndrome coronavirus 2; vaccines; viruses; zoonoses

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Emerg Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google